Findings

What do systematic reviews say?

14 questions · 14 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 21.4%GRADE not reported 0 · 0%Very low 3 · 21.4%Low 7 · 50%Moderate 0 · 0%High 1 · 7.1%

14 days inhaled AZLI plus 14 days placebo vs 28 days inhaled AZLI

FVC · children and adolescents with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 88 participants
Very low

Inhaled corticosteroids vs placebo

FVC (% predicted) Change from baseline · people with bronchiectasis

1 finding from 1 review

Inhaled corticosteroids for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Low

Short‐acting inhaled beta‐2 agonists vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FVC (% predicted) compared with placebo (very low certainty).

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 100 participants
Very low

Short‐acting inhaled muscarinic antagonists vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

FVC (% predicted) Change from baseline · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Low

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

FVC · adults, children and young people with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1261 participants
Low

Inhaled corticosteroids vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 250 participants
Low

Inhaled tobramycin (TNS) plus oral azithromycin vs TNS plus oral placebo

FVC (% predicted) Change from baseline · children with cystic fibrosis and a new culture positive for P aeruginosa

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
18 participants
Low

Summary of findings: anti‐pseudomonal antibiotics vs placebo

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1097 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Change in FVC · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
High